SAVE THE DATE to discover our last ibSium®’s clinical results at UEG Week

Share this article:

NEws Item

Join us at the Virtual Week 2020 organized by UEG (United European Gastroenterology) from October 11th to 13th and discover our last clinical results which reinforce the high efficacy of IbSium® to alleviate gastrointestinal symptoms and improve the quality of life.

“Saccharomyces cerevisiae CNCM I-3856 in IBS predominant constipation: a randomized, double-blind, placebo-controlled, multicenter clinical trial” is the title of the poster that will be held by Arnaud Bourreille, Gastroenterologist at the Institute for Digestive Tract Diseases, (Nantes-France).

IbSium® is our unique and patented probiotic yeast S. cerevisiae CNCM I-3856. Do not miss the opportunity to learn more about one of the most documented probiotic for a daily and complete digestive comfort.

101 rue de Menin
59700 Marcq-en-Baroeul

Subscribe to our newsletter

The latest news, articles, and resources, sent to your inbox twice a month.

The information provided here is, to the best of our knowledge, true and accurate. However, our products must only be used in compliance with local laws and regulations. We cannot guarantee the freedom of use for every intended application or country. These statements may not have been evaluated by your local Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. A healthy, balanced and diversified diet should fulfill all nutritional needs.